Abstract
Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Volume: 12 Issue: 4
Author(s): Zahra Shaghaghi and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Abstract: Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Export Options
About this article
Cite this article as:
Shaghaghi Zahra and Hosseinimehr Jalal Seyed*, Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (4) . https://dx.doi.org/10.2174/1574892812666170829150057
DOI https://dx.doi.org/10.2174/1574892812666170829150057 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Testosterone and Diabetes
Current Diabetes Reviews Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Colloidal Carrier Systems for Transcutaneous Immunization
Current Drug Targets The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: New Insight into Lipid Disorders)
Current Medicinal Chemistry Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Computer-Aided Detection (CADe) System for Detection of Malignant Lung Nodules in CT Slices - a Key for Early Lung Cancer Detection
Current Medical Imaging The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy The Therapeutic Potential of Chemokines in the Treatment of Chemotherapy- Induced Peripheral Neuropathy
Current Drug Targets Molecular Targeted Therapy in Enteropancreatic Neuroendocrine Tumors: From Biology to Clinical Practice
Current Medicinal Chemistry Discovery of Small Molecule Fusion Inhibitors Targeting HIV-1 gp41
Current Pharmaceutical Design Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets